ES2572145T3 - Inhibición de la angiogénesis mediante alcaloides de cefalotoxina, derivados, composiciones y usos de los mismos - Google Patents

Inhibición de la angiogénesis mediante alcaloides de cefalotoxina, derivados, composiciones y usos de los mismos

Info

Publication number
ES2572145T3
ES2572145T3 ES03765931T ES03765931T ES2572145T3 ES 2572145 T3 ES2572145 T3 ES 2572145T3 ES 03765931 T ES03765931 T ES 03765931T ES 03765931 T ES03765931 T ES 03765931T ES 2572145 T3 ES2572145 T3 ES 2572145T3
Authority
ES
Spain
Prior art keywords
angiogenesis
inhibition
cephalotoxin
alkaloids
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03765931T
Other languages
English (en)
Spanish (es)
Inventor
Dennis M Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Application granted granted Critical
Publication of ES2572145T3 publication Critical patent/ES2572145T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
ES03765931T 2002-07-22 2003-07-22 Inhibición de la angiogénesis mediante alcaloides de cefalotoxina, derivados, composiciones y usos de los mismos Expired - Lifetime ES2572145T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39765702P 2002-07-22 2002-07-22
PCT/US2003/022926 WO2004009030A2 (en) 2002-07-22 2003-07-22 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof

Publications (1)

Publication Number Publication Date
ES2572145T3 true ES2572145T3 (es) 2016-05-30

Family

ID=30771096

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03765931T Expired - Lifetime ES2572145T3 (es) 2002-07-22 2003-07-22 Inhibición de la angiogénesis mediante alcaloides de cefalotoxina, derivados, composiciones y usos de los mismos

Country Status (7)

Country Link
US (2) US7642252B2 (https=)
EP (1) EP1539179B1 (https=)
JP (1) JP2005537282A (https=)
AU (1) AU2003254120B2 (https=)
CA (1) CA2493544A1 (https=)
ES (1) ES2572145T3 (https=)
WO (1) WO2004009030A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US7135481B2 (en) * 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
WO2005087221A1 (en) * 2004-03-15 2005-09-22 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
WO2005117893A2 (en) * 2004-06-04 2005-12-15 Chemgenex Pharmaceuticals, Inc. Methods of treating cellular proliferative disease using naphthalimide and parp-1 inhibitors
CA2597323A1 (en) * 2005-02-10 2006-08-17 Chemgenex Pharmaceuticals, Inc. Medical devices
JP5550546B2 (ja) * 2007-04-13 2014-07-16 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド 経口セファロタキシン剤形
EP2260041A4 (en) 2008-03-03 2012-04-25 Sloan Kettering Inst Cancer CEPHALOTAXUS ESTERS, METHOD FOR THEIR SYNTHESIS AND USES THEREOF
US20120283306A1 (en) * 2011-04-27 2012-11-08 Georgia Health Sciences University Mouse model for avm
KR102066684B1 (ko) * 2018-02-19 2020-01-15 가천대학교 산학협력단 개비자나무 추출물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 자가면역질환의 예방 또는 치료용 조성물
KR102174166B1 (ko) * 2018-12-13 2020-11-04 영남대학교 산학협력단 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
KR102066683B1 (ko) * 2019-09-16 2020-01-15 가천대학교 산학협력단 개비자나무 추출물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 자가면역질환의 예방 또는 치료용 조성물
KR102209386B1 (ko) * 2020-01-09 2021-02-01 영남대학교 산학협력단 호모해링토닌을 유효성분으로 함유하는 대사질환 예방 또는 치료용 약학조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3793454A (en) * 1971-11-12 1974-02-19 Us Agriculture Harringtonine and isopharringtonine for treating l1210 or p388 leukemic tumors in mice
US4152214A (en) * 1977-10-07 1979-05-01 The United States Of America As Represented By The Secretary Of Agriculture Production of homodeoxyharringtonine and other cephalotaxine esters by tissue culture
JPS5835146A (ja) * 1981-08-28 1983-03-01 Isukura Sangyo Kk ２−ケト−６−メチル−５−ヘプテン酸エチルエステルの製造方法
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
ATE355379T1 (de) 1994-04-26 2006-03-15 Childrens Medical Center Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
WO1999001118A2 (en) * 1997-07-01 1999-01-14 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
DE69919179T2 (de) * 1998-09-09 2005-07-28 Inflazyme Pharmaceuticals, Ltd., Richmond Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
US6465424B1 (en) * 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
JP2003527337A (ja) * 1999-11-12 2003-09-16 エントレメッド インコーポレイテッド 抗血管新生スケジュールに基づく治療薬の投与方法
DK1263440T3 (da) 2000-03-15 2006-10-23 Chemgenex Pharmaceuticals Inc Cephalotaxinalkaloidkombinationspræparater og anvendelser deraf
EP1274458B1 (en) * 2000-04-12 2005-09-28 ChemGenex Pharmaceuticals, Inc. Compositions containing a naphthalmide and an antiproliferative agent
WO2002003904A1 (en) 2000-06-21 2002-01-17 Shigeo Takizawa Lift device capable of performing activating motion
AU7940500A (en) * 2000-10-17 2002-04-29 Oncopharm Corp New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents
ATE369894T1 (de) * 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
CN100396286C (zh) * 2002-12-30 2008-06-25 北京大学第一医院 高三尖杉酯碱和三尖杉酯碱在制备抑制血管生成药物中的应用

Also Published As

Publication number Publication date
AU2003254120B2 (en) 2009-09-10
EP1539179A2 (en) 2005-06-15
EP1539179B1 (en) 2016-03-02
US7642252B2 (en) 2010-01-05
US20040077629A1 (en) 2004-04-22
AU2003254120A1 (en) 2004-02-09
WO2004009030A3 (en) 2004-09-10
WO2004009030A2 (en) 2004-01-29
EP1539179A4 (en) 2007-01-31
CA2493544A1 (en) 2004-01-29
JP2005537282A (ja) 2005-12-08
US20090270368A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
ES2572145T3 (es) Inhibición de la angiogénesis mediante alcaloides de cefalotoxina, derivados, composiciones y usos de los mismos
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
PE20040694A1 (es) Derivados de benzoxazolinonas
AR035371A1 (es) Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento
AR065621A1 (es) Derivados de amino-piridina, una composicion farmaceutica que los comprende y su uso como medicamento para el tratamiento de enfermedades asociadas al sistema inmune activado.
AR060635A1 (es) Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
AR032361A1 (es) Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
RU2008136198A (ru) Полимерные композиции ингибиторов сетр
HRP20080052T3 (hr) Derivati tropana supstituirani imidazopiridinom santagonističkim djelovanjem na ccr5 receptor za liječenje hiv-a i upala
AR051089A1 (es) Compuestos de triazoloquinoleina y triazolonaftiridina sustituidas
WO2003096991A3 (en) Amelioration of the development of cataracts and other opthalmic diseases
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
AR062395A1 (es) Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
AR034350A1 (es) Indazoles e indoles fusionados, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento para el tratamiento de glaucoma
AR067454A1 (es) Derivados de indano- amina, su preparacion y uso como medicamentos
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
AR014964A1 (es) Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones
RU2009128968A (ru) Производные изосорбидмононитрата для лечения повышенной внутриглазной гипертензии
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
HRP20161407T1 (hr) Derivati benzokinona za liječenje mitohondrijskih bolesti oka
RU2426734C2 (ru) Пиразолопиридины и их аналоги
HRP20010630B1 (hr) Derivati 4-heterociklil-sulfonamidil-6-metoksi-5-(2-metoksi-fenoksi)-2-piridil-pirimidina, njihova proizvodnja i upotreba kao endotelin receptor antagonista
CL2025002150A1 (es) Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo